Clinical and Molecular Manifestations of Neuromuscular and Neurogenetic Disorders of Childhood

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

Background: \- Some nerve and muscle disorders that start early in life (before age 25), like some forms of muscular dystrophy, can run in families. However, the genetic causes of these disorders are not known. Also, doctors do not fully understand how symptoms of these disorders change over time. Researchers want to learn more about genetic nerve and muscle disorders that start in childhood by studying affected people and their family members, as well as healthy volunteers.

Objectives: \- To better understand nerve and muscle disorders that start early in life and run in families.

Eligibility: * Individuals at least 4 weeks old with childhood-onset muscular and nerve disorders, including those who have a later onset of a disorder that typically has childhood onset. * Affected and unaffected family members of the individuals with muscular and nerve disorders. * Healthy volunteers at least 4 weeks old with no nerve or muscle disorders.

Design: * Participants will be screened with a physical exam and medical history. Genetic information will be collected from blood, saliva, cheek swab, or skin samples. Urine samples may also be collected. * Healthy volunteers and unaffected family members will have imaging studies of the muscles. These studies will include magnetic resonance imaging (MRI) and ultrasound scans. Results will be compared with those from the affected participants. * All participants with nerve and muscle disorders will have multiple tests, including the following: * Imaging studies of the muscles, including ultrasound and MRI scans. * Imaging studies of the bones, such as x-rays and DEXA scans. * Heart and lung function tests. * Eye exams. * Nerve and muscle electrical activity tests and biopsies. * Video and photo image collection of affected muscles. * Speech, language, and swallowing evaluation. * Lumbar puncture to collect spinal fluid for study. * Tests of movement, attention, thinking, and coordination. * Participants with nerve and muscle disorders will return to the Clinical Center every year. They will repeat the tests and studies at these visits....

Eligibility
Participation Requirements
Sex: All
Minimum Age: 1 day
Maximum Age: 100
Healthy Volunteers: t
View:

∙ Probands inclusion criteria Phase 1:

• Aged 4 weeks and older

• Documentation of a personal history of a childhood-onset, hereditary/familial, neurological disorder or later onset of a disease that more commonly has childhood onset. Acceptable documentation includes evaluation through any or all of the following evaluations done prior to enrollment.

‣ Medical history, including family history information

⁃ Physical examination

⁃ Muscle, nerve, or skin biopsy

⁃ Magnetic resonance imaging (MRI)

⁃ Electromyography (EMG)

⁃ Nerve conduction study (NCS)

⁃ Electroencephalogram (EEG)

⁃ Muscle ultrasound

⁃ Genetic, metabolic, or other laboratory testing such as increased serum Creatine Kinase (CK) and abnormal serum lactate/pyruvate ratio.

Locations
United States
Maryland
National Institutes of Health Clinical Center
RECRUITING
Bethesda
Contact Information
Primary
Sandra Donkervoort
sandra.donkervoort@nih.gov
(301) 496-0272
Backup
Carsten G Bonnemann, M.D.
bonnemanncg@mail.nih.gov
(301) 594-5496
Time Frame
Start Date: 2012-03-20
Participants
Target number of participants: 9300
Treatments
Affected probands
Affected probands over age 4 weeks and onwards with known or suspected inherited neurological disorders of childhood onset
Healthy volunteers
Healthy volunteers will be recruited for the imaging procedures in order to establish baseline and age-range matched data on the healthy, maturing muscle, spinal cord volume and dynamic breathing
Single patient on Idebenone
Single patient on IND expanded access of Idebenone
Unaffected family members
Families of affected probands with known or suspected inherited neurological disorders of childhood onset
Sponsors
Leads: National Institute of Neurological Disorders and Stroke (NINDS)

This content was sourced from clinicaltrials.gov